Profile data is unavailable for this security.
About the company
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
- Revenue in USD (TTM)255.72k
- Net income in USD-4.40m
- Incorporated2011
- Employees0.00
- LocationEndonovo Therapeutics Inc6320 Canoga Avenue, 15Th FloorWOODLAND HILLS 91367United StatesUSA
- Phone+1 (800) 489-4774
- Fax+1 (818) 230-9899
- Websitehttps://endonovo.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Stem Genetics Inc | 0.00 | -568.02k | 393.34k | 1.00 | -- | 0.21 | -- | -- | -0.013 | -0.013 | 0.00 | 0.0076 | 0.00 | -- | -- | 0.00 | -198.83 | -- | -330.32 | -- | -- | -- | -- | -- | -- | -- | 0.0241 | -- | -- | -- | -- | -- | -- | -- |
| Meso Numismatics Inc | 2.44m | -10.10m | 437.29k | 1.00 | -- | -- | -- | 0.1792 | -0.8113 | -0.8113 | 0.1959 | -1.90 | 0.438 | -- | 33.37 | -- | -181.33 | -192.08 | -- | -- | 69.97 | 60.24 | -413.98 | -821.49 | -- | -0.1106 | -- | -- | 57.49 | 116.97 | -76.03 | -- | 149.35 | -- |
| Endonovo Therapeutics Inc | 255.72k | -4.40m | 524.09k | 0.00 | -- | -- | -- | 2.05 | -0.0652 | -0.0652 | 0.0003 | -0.072 | 0.2256 | -- | -- | -- | -388.54 | -303.26 | -- | -- | 96.21 | 74.38 | -1,722.26 | -5,956.27 | -- | -1.38 | -- | -- | 85.15 | -- | -495.02 | -- | -- | -- |
| Hanyuan Biotech International Inc | 10.65m | 3.14m | 539.39k | -- | 0.0294 | 0.0064 | 0.1481 | 0.0506 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| Emo Capital Corp | -100.00bn | -100.00bn | 544.35k | 0.00 | -- | -- | -- | -- | -- | -- | -- | -0.0017 | -- | -- | -- | -- | -- | -7,495.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -138.44 | -- | -- | -- |
| Pharmagreen Biotech Inc | 1.56k | -500.66k | 597.28k | 0.00 | -- | -- | -- | 382.87 | -0.0011 | -0.0011 | 0.00 | -0.0045 | 0.0094 | -- | 3.35 | -- | -302.10 | -472.20 | -- | -- | 11.54 | -- | -32,096.15 | -- | 0.0194 | -71.71 | -- | -- | -- | -- | 80.68 | -- | -- | -- |
| Limitless X Holdings Inc | 14.21m | -8.40m | 597.62k | 12.00 | -- | -- | -- | 0.0421 | -2.10 | -2.10 | 3.58 | -3.51 | 3.73 | 1.77 | 14.40 | 1,184,068.00 | -220.35 | -- | -- | -- | 77.76 | -- | -59.15 | -- | 0.0173 | -9.02 | -- | -- | -65.83 | -- | -60.80 | -- | -- | -- |
| Molecular Pharmacology (USA) Ltd | 0.00 | -105.18k | 599.73k | 0.00 | -- | -- | -- | -- | -0.0009 | -0.0009 | 0.00 | -0.0188 | 0.00 | -- | -- | -- | -976.60 | -1,219.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 44.29 | -- | -- | -- |
| Health Advance Inc | -100.00bn | -100.00bn | 613.63k | 3.00 | -- | 0.156 | -- | -- | -- | -- | -- | 0.0212 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0356 | -- | 100.00 | -- | -21.75 | -- | -- | -- |
| Evofem Biosciences Inc | 16.01m | 47.49m | 620.60k | 37.00 | 0.001 | -- | 0.013 | 0.0388 | -5.92 | -5.92 | 0.0826 | -1.36 | 0.935 | 1.72 | 2.73 | 432,756.80 | 295.02 | -211.64 | -- | -- | 63.65 | -- | 315.54 | -1,031.55 | 0.0757 | -2.91 | -- | -- | 8.20 | -- | 164.08 | -- | -10.59 | -- |
| Scisparc Ltd | 0.00 | -6.96m | 636.32k | 3.00 | -- | 26.12 | -- | -- | -1.22 | -1.51 | 0.00 | 0.0344 | 0.00 | -- | -- | 0.00 | -92.51 | -69.39 | -152.41 | -111.07 | -- | -- | -- | -527.17 | -- | -- | 0.9371 | -- | 113.73 | -- | -97.61 | -- | -- | -- |
| Capstone Therapeutics Corp | 0.00 | -358.00k | 646.20k | 2.00 | -- | -- | -- | -- | -6.58 | -38.12 | 0.00 | -60.70 | 0.00 | -- | -- | -- | -113.46 | 141.94 | -199.60 | 173.06 | -- | -- | -- | -- | -- | -2.92 | -- | -- | -- | -- | 52.46 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -17.46m | 673.19k | 3.00 | -- | -- | -- | -- | -179.17 | -179.17 | 0.00 | -20.76 | 0.00 | -- | -- | 0.00 | -384.86 | -132.47 | -- | -185.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.42 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Family CFO, Inc.as of 31 Mar 2024 | 0.00 | 0.00% |
